SEC Form 10-Q filed by IGM Biosciences Inc.
$IGMS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $21.00 → $2.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/10/2025 | $12.00 → $2.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/10/2025 | $27.00 → $2.50 | Buy → Hold | Stifel |
| 1/10/2025 | $20.00 → $1.50 | Outperform → Sector Perform | RBC Capital Mkts |
| 1/10/2025 | Buy → Neutral | Guggenheim | |
| 12/6/2024 | $21.00 | Outperform | BMO Capital Markets |
| 10/1/2024 | $12.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 10/1/2024 | $24.00 → $12.00 | Buy → Hold | Truist |
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. "Interim data
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 21 at 8:00 a.m. GMT/ 3:00 a.m. EST in London A live webcast of the events will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at http
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
8-K - IGM Biosciences, Inc. (0001496323) (Filer)
8-K - IGM Biosciences, Inc. (0001496323) (Filer)
10-Q - IGM Biosciences, Inc. (0001496323) (Filer)
BMO Capital Markets downgraded IGM Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $21.00 previously
Morgan Stanley downgraded IGM Biosciences from Equal-Weight to Underweight and set a new price target of $2.00 from $12.00 previously
Stifel downgraded IGM Biosciences from Buy to Hold and set a new price target of $2.50 from $27.00 previously
STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial and acting CEO. Jens Lindberg started his career in the pharmaceutical industry in 1995 as a sales representative for Astra, later AstraZeneca. During a 25-year span at AstraZeneca, Jens held numerous roles in Commercial & Investor Relations, spanning local & global responsibilities as well as development of phase 2/3 programs to maximise the commercial value for o
– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed as President of IGM Autoimmunity and Inflammation – MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. These new business units will utilize and build upon IGM's platform technology to create and develop novel IgM and IgA antibodies to ad
STOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest October 1, 2021. Malene Jensen will also join the company's executive team. Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most recently as Director Global Clinical Development at Sedana Medical. She holds a PhD in Clinical Neuroscience from Karolinska Institutet in Stockholm. "We are pleased to welcome Malene and her vast cl